KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
https://pubmed.ncbi.nlm.nih.gov/38490803/Actively Recruiting
Led by Ain Shams University · Updated on 2025-05-21
60
Participants Needed
1
Research Sites
21 weeks
Total Duration
Researchers are evaluating whether dapagliflozin can reduce the risk of worsening kidney function or death from heart and kidney causes in adults with advanced chronic kidney disease CKD, including those with or without type 2 diabetes. This Phase 3 trial aims to fill a gap in knowledge since previous studies excluded patients with very low kidney function or those on dialysis. The study focuses on important questions about slowing kidney decline and reducing fatal cardiovascular and renal events in this high-risk group. Participants will be randomly assigned to receive either dapagliflozin 10 mg added to their usual care or standard care alone. The trial compares these two groups to assess if dapagliflozin improves kidney and heart outcomes. The treatment period is planned for at least one year, during which patients continue their regular medical care alongside the study interventions. During the study, participants will have their kidney function monitored through tests measuring the estimated glomerular filtration rate eGFR slope and the timing of any need for kidney replacement therapy. Hospitalizations for heart failure and overall survival will also be tracked. Safety will be assessed regularly, and the total participation time spans at least one year, with ongoing evaluations to understand the impact of dapagliflozin on advanced CKD.
CONDITIONS
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Ain Shams University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 year
Participants receive dapagliflozin 10 mg in addition to standard of care or standard of care alone to evaluate effects on kidney function.
Regular visits during treatment period
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group
https://pubmed.ncbi.nlm.nih.gov/38490803/Kamyar Kalantar-Zadeh, Tazeen H Jafar, Dorothea Nitsch...
https://pubmed.ncbi.nlm.nih.gov/34175022/José C De La Flor, Daniel Villa, Leónidas Cruzado...
https://pubmed.ncbi.nlm.nih.gov/37509547/Joaquim Barreto, Cynthia Borges, Tais Betoni Rodrigues...
https://pubmed.ncbi.nlm.nih.gov/37227937/Hiddo J L Heerspink, C David Sjöström, Niels Jongs...
https://pubmed.ncbi.nlm.nih.gov/33792669/Kyle J Foreman, Neal Marquez, Andrew Dolgert...
https://pubmed.ncbi.nlm.nih.gov/30340847/Lesley A Inker, Nwamaka D Eneanya, Josef Coresh...
https://pubmed.ncbi.nlm.nih.gov/34554658/Esperanza Moral Berrio, José C De La Flor, Minerva Arambarri Segura...
https://pubmed.ncbi.nlm.nih.gov/39202480/Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter...
https://pubmed.ncbi.nlm.nih.gov/32970396/Alistair J Roddick, Alexa Wonnacott, David Webb...
https://pubmed.ncbi.nlm.nih.gov/37880609/Ain Shams University
Lead Sponsor